About BioArctic
BioArctic is a company based in Bromma (Sweden) founded in 2003. BioArctic offers products and services including Lecanemab and BrainTransporter™ Technology. BioArctic operates in a competitive market with competitors including Biogen, Denali Therapeutics, Annexon, Entrada Therapeutics and Adamas Pharma, among others.
- Headquarter Bromma, Sweden
- Stage Public
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Bioarctic Ab (Publ)
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Latest Funding Round
$327.66 K (USD), Grant
Sep 01, 2018
-
Investors
European Union
& 1 more
-
Employee Count
Not available
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of BioArctic
BioArctic offers a comprehensive portfolio of products and services, including Lecanemab and BrainTransporter™ Technology.
Targets harmful Aβ forms for Alzheimer's disease treatment.
Enables drugs to cross the blood-brain barrier for brain disorders.
Funding Insights of BioArctic
Investors in BioArctic
BioArctic has secured backing from 2 investors, including venture fund and institutional investors. Prominent investors backing the company include European Union and EIC Fund.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Government agency and accelerator focusing on innovative startups and SMEs
|
Locked | Locked | Locked | |
|
Government entites focused on freedom, democracy, equality and the rule of law, promoting peace and stability
|
Locked | Locked | Locked |
Investor details for BioArctic
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by BioArctic
Investment portfolio details for BioArctic
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - BioArctic
Detailed financials for BioArctic
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Bioarctic Comparisons
Peer comparison for BioArctic
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of BioArctic
BioArctic operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Biogen, Denali Therapeutics, Annexon, Entrada Therapeutics and Adamas Pharma, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Therapies for neurodegenerative and immunology disorders are developed.
|
|
| Locked | Locked | Locked |
Neurodegenerative disease therapies are developed for Alzheimer's, ALS, and Parkinson's.
|
|
| Locked | Locked | Locked |
Developer of antibodies to treat complement-mediated neurodegenerative diseases
|
|
| Locked | Locked | Locked |
Biologics platform developed for intracellular delivery in rare diseases.
|
|
| Locked | Locked | Locked |
Pharmacokinetic profiles of approved drugs are enhanced for CNS therapeutics.
|
|
| Locked | Locked | Locked |
T-cell-based therapies for autoimmune and degenerative diseases are developed.
|
Detailed competitors of BioArctic
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Bioarctic
Complete news archive for BioArctic
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about BioArctic
BioArctic was founded in 2003 and raised its 1st funding round 12 years after it was founded.
BioArctic is headquartered in Bromma, Sweden. It is registered at Bromma, Stockholms Lan, Sweden.
BioArctic was founded in 2003 in Bromma, Sweden, within the biotechnology sector. Focus is placed on developing therapies that modify the course of neurodegenerative diseases. Operations involve antibody-based solutions, including Lecanemab, which targets oligomers and protofibrils for Alzheimers disease. TDP-43 protein therapies are pursued for amyotrophic lateral sclerosis, while antibodies against toxic soluble aggregates are advanced for Parkinsons disease. Research and development activities are centered in Sweden.
BioArctic's top competitors include Alector, Entrada Therapeutics and Annexon.
BioArctic offers Lecanemab and BrainTransporter™ Technology.
BioArctic has 2 investors. Key investors include European Union, and EIC Fund.